New drug IBI3014 enters first human tests for Hard-to-Treat cancers
NCT ID NCT06974812
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called IBI3014 in 250 adults with advanced solid tumors that cannot be removed by surgery. The drug is given by IV every 3 weeks at different doses. The main goals are to find the safest dose and to see if the drug can shrink tumors. This is the first time IBI3014 is being tested in humans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI3014 (an experimental drug given by IV infusion every 3 weeks)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors that cannot be removed by surgery.
- What could go wrong
- This is a very early first-in-human study, so the drug may not shrink tumors or may cause unexpected side effects. Success in early phases does not guarantee later approval.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian cancer hospital
RECRUITINGFuzhou, Fujian, 350014, China
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410000, China
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, 200433, China